An evaluation of prescription device moisturizers.
Moisturization of the skin is important for both medical and cosmetic purposes. The development of prescription device moisturizers, receiving 510K approval on the basis of the physical reduction in transepidermal water loss, provided a new dermatologic category. This investigator-blinded research utilized a split body model in 60 subjects to examine the effect of a traditional moisturizer as compared to a prescription device moisturizer in the treatment of mild to moderate symmetrical eczema of the arms or legs. This study demonstrated parity between the two moisturizers based on subject and investigator assessments.
Draelos
Zoe Diana
ZD
High Point, NC, USA. zdraelos@northstate.net
D000279:Administration, Cutaneous; D000287:Administration, Topical; D000328:Adult; D000982:Antipruritics / Q000008:administration & dosage; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004485:Eczema / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005782:Gels / Q000008:administration & dosage; D006229:Hand Dermatoses / Q000188:drug therapy; D006801:Humans; D007868:Leg Dermatoses / Q000188:drug therapy; D008297:Male; D010349:Patient Compliance; D055656:Prescriptions; D011336:Probability; D012307:Risk Factors; D012720:Severity of Illness Index; D016037:Single-Blind Method; D018709:Statistics, Nonparametric; D013501:Surface-Active Agents / Q000008:administration & dosage / Q000494:pharmacology; D016896:Treatment Outcome; D014221:Triamcinolone / Q000008:administration & dosage*; D055815:Young Adult
D000982:Antipruritics; D003879:Dermatologic Agents; D004338:Drug Combinations; D005782:Gels; D013501:Surface-Active Agents; D014221:Triamcinolone